Clinical Trials News

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Appoints Dr. Victor Sandor to its Board of Directors...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNo...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes....

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving background standard of care. In the trial, KERENDIA met the primary endpoint by showing a significant reduction in the rate of kidney disease progression, as measured by estimated glomerular filtration rate (eGFR) slope (mean annual change from baseline to month...

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed...

HOUSTON--(BUSINESS WIRE)--Goldenrod Therapeutics, innovator in brain inflammation treatments for neurological conditions, completed initial close on $6.5 million Series Seed....

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio...

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio and will be the foundation of Lakefront’s clinical de...

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei’s Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment...

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, a global leader in compact proton therapy, today announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has been completed at Stanford Medicine Cancer Center. The treatment was delivered on the MEVION S250-FIT Proton Therapy System™. The milestone establishes a new category of proton therapy delivery: a compact single-room system that fits within existing radi...